By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem hosting webinar on Solubility-directed Development of Trileucine process
Bubendorf, Switzerland: –Peptide technology specialist Bachem’s latest online webinar later this month will focus on the development of a manufacturing process for Trileucine that enables the application of this excipient also for aqueous solutions at neutral pH.
The Zoom-hosted one hour webinar: ‘Solubility-directed Development of Trileucine Process’ will take place on March 22, 2021, starting at 17:30hrs CET (UTC +1:00). Registration is free of charge and can be completed online (see Resources).
Solubility-directed Development of Trileucine Process
The excipient Trileucine is used to improve aerosol performance and stability of spray-dried powders for inhalation. Bachem had already established a Liquid-Phase Peptide Synthesis (LPPS) manufacturing process for Trileucine that yields high quality material. More recently, it has carried out further development work to allow the application of Trileucine in aqueous solutions at neutral pH to enhance the water solubility of the isolated peptide. This was already possible using spray drying, but the new process is more straightforward in allowing the Trileucine form with higher solubility in water to be directly obtained by an improved crystallization process based on the results of a polymorph screening study.
The webinar will explain more about the advantage of this development approach as well as about Trileucine properties, manufacturing, and applications in general.
Principal speaker will be Dr. Wolfgang Seufert, who is Director of Production at Bachem’s Bubendorf facility, who delivered a similar presentation as part of Bachem’s presence at the virtual TIDES Asia 2021 conference earlier in March. At Bachem, Dr. Seufert leads a team focusing on the scale-up development of manufacturing processes for peptides in solution. Since joining Bachem more than 13 years ago and working in several positions at Bubendorf and at Torrance in the USA, he has gained broad experience in development, scale up, and manufacturing of peptides, using both liquid and solid phase peptide synthesis (SPPS). Wolfgang Seufert studied chemistry in Germany at the universities of Giessen and Leipzig. After earning his Ph.D. from the University of Basel (Switzerland) for his work on cyclization reactions of modified amino acids and peptides, he worked as a post-doctoral fellow at the Life Sciences Institute of the University of Michigan (USA).
The webinar will be moderated by Bachem Business Development Manager Laura Milbrandt, who is located in Boulder, Colorado and is the primary contact for Bachem partners in the Western United States region in the area of GMP peptide API manufacture and development, supporting customers through all project phases, from preclinical research and IND enabling toxicology studies to process validation and commercialization. Laura joined Bachem nearly three years ago from a background in Business Development and Project Management for API development. She earned master’s degrees in Biotechnology and Business from California State University, Channel Islands.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com
Click on Bachem webinar ‘Solubility-directed Development of Trileucine Process’ to register for the event.